

# Annamaria Offidani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/212740/publications.pdf>

Version: 2024-02-01

97  
papers

1,955  
citations

218677

26  
h-index

315739

38  
g-index

99  
all docs

99  
docs citations

99  
times ranked

2534  
citing authors

#	ARTICLE	IF	CITATIONS
1	A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1146-1149.	2.2	19
2	New insight into old and new antimicrobial molecules targeting quorum sensing for MRSA wound infection. <i>Future Microbiology</i> , 2022, 17, 177-183.	2.0	3
3	Grooved Probe Nail Surgery: A Pandemicâ€“Induced Approach. <i>Dermatologic Surgery</i> , 2022, 48, 471-472.	0.8	0
4	Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, 1-78.	0.2	25
5	Sofpironium bromide: an investigational agent for the treatment of axillary hyperhidrosis. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 15-21.	4.1	3
6	The Double-Edged Sword of Oxidative Stress in Skin Damage and Melanoma: From Physiopathology to Therapeutical Approaches. <i>Antioxidants</i> , 2022, 11, 612.	5.1	43
7	Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities. <i>Journal of Clinical Medicine</i> , 2022, 11, 2422.	2.4	0
8	Methicillin-resistant <i>Staphylococcus aureus</i> as a cause of chronic wound infections: Alternative strategies for management. <i>AIMS Microbiology</i> , 2022, 8, 125-137.	2.2	12
9	The pharmacological treatment and management of hyperhidrosis. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1217-1231.	1.8	7
10	Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1585-1592.	3.1	5
11	Evidence for a â€“window of opportunityâ€™ in hidradenitis suppurativa treated with adalimumab: a retrospective, realâ€“life multicentre cohort study*. <i>British Journal of Dermatology</i> , 2021, 184, 133-140.	1.5	88
12	Management of patients with pemphigus vulgaris during the COVIDâ€“19 pandemic: Experience of a second level dermatology center. <i>Australasian Journal of Dermatology</i> , 2021, 62, e158-e159.	0.7	4
13	Hydroxychloroquine, dermatology, and SARSâ€“CoVâ€“2: Updating an old association. <i>Journal of Medical Virology</i> , 2021, 93, 5-7.	5.0	2
14	Telogen effluvium related to post severe Sarsâ€“Covâ€“2 infection: Clinical aspects and our management experience. <i>Dermatologic Therapy</i> , 2021, 34, e14547.	1.7	37
15	Paraoxonaseâ€“2: A potential biomarker for skin cancer aggressiveness. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13452.	3.4	34
16	Characterization of Hidradenitis Suppurativa Phenotypes: A Multidimensional Latent Class Analysis of the National Italian Registry IRHIS. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1236-1242.e1.	0.7	22
17	The efficacy of in vivo administration of Apremilast on mesenchymal stem cells derived from psoriatic patients. <i>Inflammation Research</i> , 2021, 70, 79-87.	4.0	5
18	Vaccines for COVID-19 in patients with atopic dermatitis: three things every dermatologist should know. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2021, 30, .	0.1	1

#	ARTICLE	IF	CITATIONS
19	Ixekizumab for treatment of moderate to severe plaque psoriasis: real world clinical experience. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2021, 155, 739-743.	0.8	9
20	Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-centre experience. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 939-940.	1.3	5
21	Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 223-232.	2.0	23
22	Oxidative Stress and Alterations of Paraoxonases in Atopic Dermatitis. <i>Antioxidants</i> , 2021, 10, 697.	5.1	18
23	Safety and Efficacy of Vaccines during COVID-19 Pandemic in Patients Treated with Biological Drugs in a Dermatological Setting. <i>Healthcare (Switzerland)</i> , 2021, 9, 401.	2.0	8
24	Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e428-e430.	2.4	13
25	Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic: a look into the past for a conscious vaccination management. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3268-3275.	3.3	3
26	Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma. <i>Human Cell</i> , 2021, 34, 1929-1931.	2.7	18
27	Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy. <i>Dermatology and Therapy</i> , 2021, 11, 1889-1903.	3.0	6
28	Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers. <i>Cancers</i> , 2021, 13, 4943.	3.7	37
29	How to fight SARS-COV-2 vaccine hesitancy in patients suffering from chronic and immune-mediated skin disease: four general rules. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4105-4107.	3.3	3
30	Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model. <i>Antibiotics</i> , 2021, 10, 1210.	3.7	10
31	Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience. <i>Dermatologic Therapy</i> , 2021, 34, e15179.	1.7	7
32	A tricky case of contact dermatitis: Simultaneous allergic reaction to topical and oral acyclovir, and scar gel. <i>Contact Dermatitis</i> , 2021, 84, 203-205.	1.4	0
33	New Perspectives on Old and New Therapies of Staphylococcal Skin Infections: The Role of Biofilm Targeting in Wound Healing. <i>Antibiotics</i> , 2021, 10, 1377.	3.7	11
34	Vaccines for COVID-19 in patients with atopic dermatitis: three things every dermatologist should know. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2021, 30, 67-69.	0.1	0
35	The effect of dupilumab in an HBV-HIV coinfecting atopic patient: a case report. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2021, 30, 71-73.	0.1	0
36	Plasma oxidation status and antioxidant capacity in psoriatic children. <i>Archives of Dermatological Research</i> , 2020, 312, 33-39.	1.9	18

#	ARTICLE	IF	CITATIONS
37	Differential expression of nicotinamide Nâ€methyltransferase in cutaneous keratoacanthoma and squamous cell carcinoma: an immunohistochemical study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e121-e123.	2.4	2
38	Time to restart: protocol of resumption of activities of a dermatological clinic of a level II hospital in the COVIDâ€19 era. <i>International Journal of Dermatology</i> , 2020, 59, 1411-1413.	1.0	3
39	Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study. <i>Dermatologic Therapy</i> , 2020, 33, e14039.	1.7	12
40	Management of patients with hidradenitis suppurativa during the COVIDâ€19 pandemic: Risk and benefit of immunomodulatory therapy. <i>Dermatologic Therapy</i> , 2020, 33, e14256.	1.7	7
41	Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1019-1037.	3.3	7
42	Paraoxonase-2 Silencing Enhances Sensitivity of A375 Melanoma Cells to Treatment with Cisplatin. <i>Antioxidants</i> , 2020, 9, 1238.	5.1	37
43	Active implications for dermatologists in â€SARSâ€CoVâ€2 ERAâ€™: Personal experience and review of literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1626-1632.	2.4	20
44	How can I take care of you? The dermatologist meets patients' needs during the COVIDâ€19 pandemic. <i>Dermatologic Therapy</i> , 2020, 33, e13740.	1.7	14
45	Skin involvement in SARSâ€CoVâ€2 infection: Case series. <i>Journal of Medical Virology</i> , 2020, 92, 2332-2334.	5.0	44
46	Global coronavirus pandemic ( SARSâ€CoV â€2): Past , present , and future of pediatric dermatology. <i>Dermatologic Therapy</i> , 2020, 33, e13767.	1.7	3
47	Safety update of etanercept treatment for moderate to severe plaque psoriasis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 439-448.	2.4	13
48	Global coronavirus pandemic (2019â€nCOV): implication for an Italian medium size dermatological clinic of a II level hospital. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e213-e214.	2.4	50
49	New Evidence and Insights on Dalbavancin and Wound Healing in a Mouse Model of Skin Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	23
50	Efficacy of oral zinc and nicotinamide as maintenance therapy for mild/moderate hidradenitis suppurativa: A controlled retrospective clinical study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 665-667.	1.2	22
51	Novel Therapeutic Approaches and Targets for Treatment of Psoriasis. <i>Current Pharmaceutical Biotechnology</i> , 2020, 22, 7-31.	1.6	22
52	Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA). <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 1-7.	0.8	18
53	Psoriasis and its management in women of childbearing age: tools to increase awareness in dermatologists and patients. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 434-440.	0.8	7
54	Novel Therapeutic Approaches and Targets for the Treatment of Neutrophilic Dermatoses, Management of Patients with Neutrophilic Dermatoses and Future Directions in the Era of Biologic Treatment. <i>Current Pharmaceutical Biotechnology</i> , 2020, 22, 46-58.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease. <i>Current Pharmaceutical Biotechnology</i> , 2020, 22, 32-45.	1.6	2
56	Pharmacodynamics OF TNF $\hat{\pm}$ inhibitors for the treatment of psoriasis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 913-925.	3.3	24
57	Nicotinamide Nâ€methyltransferase in nonmelanoma skin cancers. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13175.	3.4	22
58	Hidradenitis suppurativa in a prepubertal case series: a call for specific guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 28-31.	2.4	25
59	Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian Ultrasound Working Group experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 10-14.	2.4	33
60	Hidradenitis suppurativa epidemiology: from the first Italian registry in 2009 to the most recent epidemiology updates â€“ Italian Registry Hidradenitis Suppurativa project 2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 4-6.	2.4	10
61	Metabolic, pharmacokinetic, and toxicological issues surrounding dapsons. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 367-379.	3.3	26
62	Efficacy of Pexiganan Combination with Tigecycline in a Mouse Model of Pseudomonas aeruginosa Sepsis. <i>Current Topics in Medicinal Chemistry</i> , 2019, 18, 2127-2132.	2.1	7
63	Nicotinamide N-methyltransferase: potential involvement in cutaneous malignant melanoma. <i>Melanoma Research</i> , 2018, 28, 82-88.	1.2	35
64	Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- $\hat{\pm}$ Inhibitors. <i>Current Pharmaceutical Biotechnology</i> , 2018, 18, 945-963.	1.6	8
65	Photoprotection and photodermatitis: a case. <i>Contact Dermatitis</i> , 2017, 76, 54-55.	1.4	3
66	Role of Daptomycin on Burn Wound Healing in an Animal Methicillin-Resistant Staphylococcus aureus Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	32
67	<scp>TNF</scp> $\hat{\pm}$ inhibitors reduce the pathological Th<sub>1</sub>â€“Th<sub>17</sub>/Th<sub>2</sub> imbalance in cutaneous mesenchymal stem cells of psoriasis patients. <i>Experimental Dermatology</i> , 2017, 26, 319-324.	2.9	40
68	The effect of low-carbohydrates calorie-restricted diet on visceral adipose tissue and metabolic status in psoriasis patients receiving TNF-alpha inhibitors: results of an open label controlled, prospective, clinical study. <i>Journal of Dermatological Treatment</i> , 2017, 28, 206-212.	2.2	11
69	Treatment patterns with systemic antipsoriatic agents in childhood psoriasis: an Italian database analysis. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 327-332.	0.2	7
70	Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background. <i>World Journal of Cardiology</i> , 2016, 8, 120.	1.5	36
71	Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts. <i>Current Drug Safety</i> , 2016, 11, 35-43.	0.6	24
72	Biologic Therapy in Psoriasis: Safety Profile. <i>Current Drug Safety</i> , 2016, 11, 4-11.	0.6	27

#	ARTICLE	IF	CITATIONS
73	Anti-TNF- $\alpha$ treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells. <i>Oncotarget</i> , 2016, 7, 11945-11958.	1.8	69
74	Non-alcoholic fatty liver disease and psoriasis: So far, so near. <i>World Journal of Hepatology</i> , 2015, 7, 315.	2.0	51
75	Homocysteine plasma levels in psoriasis patients: our experience and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1781-1785.	2.4	43
76	Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art. <i>Skin Appendage Disorders</i> , 2015, 1, 6-13.	1.0	20
77	Involvement of the oral cavity in psoriasis: results of a clinical study. <i>British Journal of Dermatology</i> , 2015, 172, 282-285.	1.5	40
78	Clinical and prognostic significance of survivin, AKT and VEGF in primary mucosal oral melanoma. <i>Anticancer Research</i> , 2015, 35, 2113-20.	1.1	12
79	Insulin resistance, serum insulin and HOMA-R. <i>Journal of Gastroenterology</i> , 2013, 48, 673-673.	5.1	14
80	Adalimumab Modulates Angiogenesis in Psoriatic Skin. <i>European Journal of Inflammation</i> , 2013, 11, 489-498.	0.5	30
81	The Efficacy of the Quorum Sensing Inhibitor FS8 and Tigecycline in Preventing Prosthesis Biofilm in an Animal Model of Staphylococcal Infection. <i>International Journal of Molecular Sciences</i> , 2013, 14, 16321-16332.	4.1	37
82	Tigecycline accelerates staphylococcal-infected burn wound healing through matrix metalloproteinase-9 modulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 191-201.	3.0	30
83	Antimicrobial properties of distinctin in an experimental model of MRSA-infected wounds. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 3047-3055.	2.9	18
84	Effectiveness of antimicrobial photodynamic therapy with a single treatment of RLPO68/CI in an experimental model of Staphylococcus aureus wound infection. <i>British Journal of Dermatology</i> , 2011, 164, 987-995.	1.5	66
85	<i>In vitro</i> activity of the lipopeptide derivative (Pal-lys-lys-NH <sub>2</sub> ), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. <i>British Journal of Dermatology</i> , 2009, 161, 249-252.	1.5	17
86	Comparative Efficacy of Topical Versus Systemic Teicoplanin in Experimental Model of Wound Infections. <i>Journal of Surgical Research</i> , 2008, 144, 74-81.	1.6	10
87	Temporin A is effective in MRSA-infected wounds through bactericidal activity and acceleration of wound repair in a murine model. <i>Peptides</i> , 2008, 29, 520-528.	2.4	33
88	RNAIII-Inhibiting Peptide Enhances Healing of Wounds Infected with Methicillin-Resistant Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2205-2211.	3.2	66
89	Cutaneous carcinomas and preinvasive neoplastic lesions. Role of MMP-2 and MMP-9 metalloproteinases in neoplastic invasion and their relationship with proliferative activity and p53 expression. <i>Journal of Cutaneous Pathology</i> , 2001, 28, 120-126.	1.3	29
90	Guess what! Acute haemorrhagic oedema of the skin in infancy. <i>European Journal of Dermatology</i> , 2001, 11, 63-4.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Role of Cytomegalovirus Replication in Alopecia Areata Pathogenesis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2000, 4, 63-65.	1.2	22
92	Papillary hidradenoma: immunohistochemical analysis of steroid receptor profile with a focus on apocrine differentiation. <i>Journal of Clinical Pathology</i> , 1999, 52, 829-832.	2.0	39
93	Hypomelanosis of Ito: a case report with clinical and ultrastructural data. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1998, 10, 73-76.	2.4	4
94	Subclinical Joint Involvement in Psoriasis: Magnetic Resonance Imaging and X-ray Findings. <i>Acta Dermato-Venereologica</i> , 1998, 78, 463-465.	1.3	111
95	Skin metastases from prostate cancer associated with malignant melanoma. <i>Cutis</i> , 1997, 59, 278-80.	0.3	4
96	Immunohistochemical localization of TGF- $\beta$ 2 in the skin of patients with alopecia areata. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1996, 7, 75-90.	2.4	3
97	Immunohistochemical localization of TGF- $\beta$ 2 in the skin of patients with alopecia areata. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1996, 7, 75-77.	2.4	1